Results 101 to 110 of about 1,866 (169)

Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years

Arthritis Research & Therapy
Background Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to 2 years in patients with axial spondyloarthritis (axSpA).
Sofia Ramiro, Fabian Proft, Raj Sengupta, Astrid van Tubergen, Anna Moltó, Lianne S. Gensler, Mitsumasa Kishimoto, Vanessa Taieb, Sarah Kavanagh, Shawna Evans, Victoria Navarro-Compán   +10 more
doaj   +1 more source

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Rheumatology and Therapy
Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors ...
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes   +8 more
doaj   +1 more source

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study

Journal of Dermatological Treatment
Objectives Bimekizumab, a dual interleukin (IL)-17A/IL-17F inhibitor, has demonstrated clinical efficacy in clinical trials. However, real-world evidence comparing outcomes according to previous biologic exposure remains limited.
Emanuele Trovato, Antonella Di Cesare, Salvatore Panduri, Leonardo Pescitelli, Federica Ricceri, Sofia Lo Conte, Luca Brandini, Aldo Cuccia, Marco Romanelli, Pietro Rubegni, Francesca Prignano   +10 more
doaj   +1 more source

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study

Bimekizumab is a novel interleukin (IL)-17A/IL-17F inhibitor approved for the treatment of moderate-to-severe plaque psoriasis in adult patients. While its efficacy and safety have been demonstrated in several clinical trials, real-world data remains ...
Sood, S (via Mendeley Data), Sood, Siddhartha   +1 more
core   +1 more source

OA16 Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two Phase 3 studies

Rheumatology
The impact of dual inhibition of interleukin (IL)17F in addition to IL-17A with bimekizumab (BKZ) on structural lesions in axial spondyloarthritis (axSpA) patients has not yet been shown.
W. Maksymowych, S. Ramiro, D. Poddubnyy, X. Baraliakos, Robert G. W. Lambert, U. Massow, T. Vaux, C. Prajapati, Alexander Marten, N. de Peyrecave, M. Østergaard   +10 more
semanticscholar   +1 more source

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Rheumatology and Therapy
Introduction Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic arthritis ...
Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease   +8 more
doaj   +1 more source

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis

RMD Open
Background Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase ...
S. Ramiro, D. Poddubnyy, P. Mease, C. López-Medina, Mindy Kim, U. Massow, V. Taieb, T. Kragstrup, D. McGonagle   +8 more
semanticscholar   +1 more source

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.

OBJECTIVES: To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of interleukin-17F in addition to IL-17A, vs other biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for psoriatic arthritis
Laliman-Khara, Victor, Coates, Laura C, Gladman, Dafna D, Merola, Joseph F, Willems, Damon, Taieb, Vanessa, Grieve, Stacy, Prickett, Adam R, Nash, Peter, Mease, Philip   +9 more
core   +1 more source

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison

Rheumatology and Therapy
Introduction Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the treatment of psoriatic arthritis (PsA) in patients who were biologic disease-modifying anti-
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes   +8 more
doaj   +1 more source

Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature

Clinical, Cosmetic and Investigational Dermatology
Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory disorder of the hair follicles affecting areas rich in apocrine glands. Moderate-to-severe forms often require biologic therapies, including bimekizumab, a humanized monoclonal ...
F. Martora, M. Megna
semanticscholar   +1 more source